On August 14, 2026, Vestal Point Capital, LP filed a Schedule 13G/A with the SEC, reporting a 3.5% ownership stake in Immunocore Holdings plc (IMCR). The filing indicates that the reporting persons, including Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder, beneficially own 1,800,000 American Depo...

Sirenia Capital Management LP, along with Alex Silverstein, filed a Schedule 13G/A on August 14, 2026, disclosing a position in Immunome Inc. (IMNM). As of the event date of June 30, 2026, the reporting persons beneficially own 4,832,279 shares of Common Stock, representing 4.3% of the class based on 113,250,394 shares...

T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A on August 14, 2026, disclosing a significant increase in its stake in Immunome Inc (IMNM). As of the event date of June 30, 2026, the firm beneficially owns 19,676,883 shares of common stock, representing a 17.4% ownership stake in the company. This marks...

On August 14, 2026, Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen filed a Schedule 13G/A (Amendment No. 2) regarding their holdings in InflaRx N.V. The filing reveals that the reporting group collectively beneficially owns 22,933,910 common shares, representing 15.6% of the company. Specifically, A...

Nantahala Capital Management, LLC, along with its principals Wilmot B. Harkey and Daniel Mack, filed a Schedule 13G/A on August 14, 2026, reporting a new beneficial ownership position in Inhibikase Therapeutics, Inc. (IKT). As of the event date on June 30, 2026, the reporting persons collectively held 5,810,487 shares ...

On August 14, 2026, Perceptive Advisors LLC, alongside Joseph Edelman and the Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G/A reporting a 6.9% ownership stake in Inhibikase Therapeutics, Inc. (IKT). The reporting persons beneficially own 10,320,875 shares of common stock, which are held through vario...

Viking Global Investors LP (VGI) and associated reporting persons, including O. Andreas Halvorsen and Rose S. Shabet, filed a Schedule 13G/A on August 14, 2026, disclosing a 9.3% ownership stake in Inhibrx Biosciences, Inc. (INBX). The reporting group beneficially owns 1,383,621 shares of Common Stock, which includes 1...

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G/A on August 14, 2026, disclosing a significant ownership position in Inhibrx Biosciences, Inc. (INBX). The reporting persons collectively hold 1,489,443 shares of common stock, representing a 9.99% st...

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G/A on August 14, 2026, regarding their holdings in Invivyd, Inc. (IVVD). The filing reveals that the reporting persons now collectively beneficially own 18,490,636 shares of Common Stock, representing ...

Venrock Healthcare Capital Partners and its affiliated entities, including Nimish Shah and Bong Koh, filed a Schedule 13G/A on August 14, 2026, disclosing an 8.3% ownership stake in Jade Biosciences, Inc. (JBIO). The reporting group collectively beneficially owns 5,145,330 shares of common stock as of June 30, 2026. Th...

On August 14, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Janux Therapeutics, Inc. (JANX). The filing reports that the reporting persons beneficially own 1,993,837 shares of common stock, representi...

Lynwood Capital Management Inc., alongside Ben Shapiro and Lynwood Opportunities Master Fund, filed an amended Schedule 13G on August 14, 2026, regarding their holdings in Kazia Therapeutics Limited (KZIA). The filing indicates that as of June 30, 2026, the reporting persons beneficially own 264,980,500 ordinary shares...